Merck and Co Inc (MRK)

[north40000]

"A combination with Zocor[a statin] might make sense, but Zocor has been off-patent for several years, and MRK no longer has any interest in it."

IMO, MRK might well be interested in buying Amarin, with AMRN's NCE status for Vascepa, a patent portfolio encompassing Vascepa + statins extending to 2030, analyst projections of market/revenue size, continued increase in prescriptions as well as market share[now > %50% vis a vis Lovaza or gLovaza], and PTs of $30-50 per share reflecting Vascepa market of > $10B. My own off-label scrip for FDA-approved Vascepa of 6+ years duration has resulted, in light of insurance coverage, in my total co-pay of $36/year.

Original post in this thread, all links included:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151534457